Preface The following was the result of discussion and collaboration between MS Money Moves and SCYNEXIS (Nasdaq: SCYX) Chief Financial Officer Eric Francois. We are thankful for his time and … [Read more...] about Interview with SCYNEXIS Following Positive Interim-Results From Phase 3 Open-Label FURI Study
Intercept Announces Positive Top-Line Data From Phase 3 Study In Liver Fibrosis
On the heels of Gilead's (NYSE: GILD) disappointing phase 3 data readout in compensated cirrhosis from NASH (F4); Intercept Pharmaceutical (NYSE: ICPT) announced today positive results from their … [Read more...] about Intercept Announces Positive Top-Line Data From Phase 3 Study In Liver Fibrosis
ADMA Enters Into $72.5 Million Loan Facility With Perceptive Advisors
Today ADMA Biologics (Nasdaq: ADMA) announced that they entered into a senior secured loan term facility with Perceptive Advisors for up to $72.5 million under 2 funding tranches. Let's get clarify … [Read more...] about ADMA Enters Into $72.5 Million Loan Facility With Perceptive Advisors
GALT Director Sells 30K Shares
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. A form-4 just filed on 02/04/2019 by Galectin Therapeutics (Nasdaq: GALT) reports that GALT director … [Read more...] about GALT Director Sells 30K Shares
MS Identified Its Next Swing
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Preface WOW. We are absolutely elated with the performance of our last swing move on SCYX. In case you missed it on … [Read more...] about MS Identified Its Next Swing
SCYX Swing Move
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Swing Thesis SCYNEXIS (Nasdaq: SCYX $.73) has been identified as a potentially lucrative swing move. … [Read more...] about SCYX Swing Move